Jon Congleton, Mineralys Therapeutics CEO
After hypertension competitor gets bought, Mineralys lines up IPO plans
Mineralys Therapeutics has penciled in a $100 million initial public offering to take its investigational hypertension drug into Phase III testing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
